In a recalibrated viewpoint following a subdued quarterly performance, Prabhudas Lilladher has reiterated its BUY call on Infosys, adjusting its target price downward from Rs 2,020 to Rs 1,630.
Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).